Effective January 1, 2023, David Liu, Protagonist Therapeutics, Inc.'s Chief R&D Strategy Officer, transitioned to a part-time R&D Strategy Advisor due to health reasons. In his new role, Dr. Liu is no longer a Section 16 or executive officer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
34.65 USD | +8.69% |
|
+7.41% | +51.11% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+51.11% | 2.03B | |
+19.41% | 45.51B | |
-8.62% | 38.52B | |
+38.65% | 38.13B | |
+26.95% | 30.74B | |
-13.50% | 26.03B | |
+10.74% | 25.92B | |
+44.87% | 14.13B | |
+34.36% | 12.73B | |
-7.14% | 11.29B |
- Stock Market
- Equities
- PTGX Stock
- News Protagonist Therapeutics, Inc.
- Protagonist Therapeutics, Inc. Announces David Liu, Chief R&D Strategy Officer, Transitioned to Part-Time R&D Strategy Advisor